Syncom Formulations: AGM Results - All Resolutions Passed on 29 Sep 2025
The passing of resolutions is a routine part of corporate governance and doesn't necessarily indicate a significant change in the company's prospects.
All resolutions were passed successfully, indicating positive shareholder agreement and corporate governance.
* Syncom Formulations (India) Limited held its 37th Annual General Meeting (AGM) on 29th September 2025. * The chairman declared the results of the remote e-voting and e-voting at the AGM on 1st October 2025. * All eight resolutions presented at the AGM were passed with the requisite majority. * Resolutions included: * Adoption of audited financial statements for the year ended 31st March 2025. * Ratification of remuneration of the Cost Auditor for FY 2025-26. * Confirmation of the appointment of M/s D.K. Jain & Co. as Secretarial Auditors. * Confirmation of the appointment of Shri Ankit Kedarmal Bankda as a Director. * Approval of Shri Ankit Kedarmal Bankda as Executive Chairman and Whole-time Director, including remuneration. * Approval for increase in remuneration payable to Mr. Rahul Vijay Bankda, CFO. * Alteration in the Articles of Association (AOA) and Memorandum of Association (MOA) of the Company.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.